LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong

Stock News

01/27

Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The transferred shares had a market value of HK$454 million, representing a 3.88% stake. LUYE PHARMA announced that on January 26, 2026, Shenzhen Luye, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing Luye entered into a capital injection agreement. Under this agreement, Nanjing Xin'an and Ningbo Xinda agreed to provide Nanjing Luye with additional capital totaling RMB 285 million. Following the completion of the capital injection, Nanjing Luye will be 70.01% owned by Shenzhen Luye, 23.34% by Nanjing Xinshi, 4.32% by Nanjing Xin'an, and 2.33% by Ningbo Xinda.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1141447932"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141447932\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141447932?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141447932","market":"other","top_or_hot":-1,"title":"LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong","media":"Stock News","content":"<p>Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The transferred shares had a market value of HK$454 million, representing a 3.88% stake.\nLUYE PHARMA announced that on January 26, 2026, Shenzhen Luye, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing Luye entered into a capital injection agreement. Under this agreement, Nanjing Xin'an and Ningbo Xinda agreed to provide Nanjing Luye with additional capital totaling RMB 285 million.\nFollowing the completion of the capital injection, Nanjing Luye will be 70.01% owned by Shenzhen Luye, 23.34% by Nanjing Xinshi, 4.32% by Nanjing Xin'an, and 2.33% by Ningbo Xinda.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-27 08:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The transferred shares had a market value of HK$454 million, representing a 3.88% stake.\nLUYE PHARMA announced that on January 26, 2026, Shenzhen Luye, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing Luye entered into a capital injection agreement. Under this agreement, Nanjing Xin'an and Ningbo Xinda agreed to provide Nanjing Luye with additional capital totaling RMB 285 million.\nFollowing the completion of the capital injection, Nanjing Luye will be 70.01% owned by Shenzhen Luye, 23.34% by Nanjing Xinshi, 4.32% by Nanjing Xin'an, and 2.33% by Ningbo Xinda.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1141447932","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141447932","pubTimestamp":1769475499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","BK1191":"制药","BK1606":"中医药概念","02186":"绿叶制药","BK1583":"高瓴概念"},"translate_title":"绿叶制药(02186)股东向瑞银证券香港转让建银国际证券价值4.54亿港元股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"02186":1},"content_text":"Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The transferred shares had a market value of HK$454 million, representing a 3.88% stake.\nLUYE PHARMA announced that on January 26, 2026, Shenzhen Luye, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing Luye entered into a capital injection agreement. Under this agreement, Nanjing Xin'an and Ningbo Xinda agreed to provide Nanjing Luye with additional capital totaling RMB 285 million.\nFollowing the completion of the capital injection, Nanjing Luye will be 70.01% owned by Shenzhen Luye, 23.34% by Nanjing Xinshi, 4.32% by Nanjing Xin'an, and 2.33% by Ningbo Xinda.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}